{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:52:55Z","timestamp":1793087575964,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Institutes of Health (NIH)","award":["R56 AI093763-01"],"award-info":[{"award-number":["R56 AI093763-01"]}]},{"name":"RO1 MH 071456"},{"name":"Lyme Research Alliance"},{"name":"Lyme and Tick-borne Diseases Research Center at Columbia University Medical Center"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jneuroim.2012.10.011","type":"journal-article","created":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T05:47:26Z","timestamp":1352353646000},"page":"85-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Increased IFN\u03b1 activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits"],"prefix":"10.1016","volume":"255","author":[{"given":"Elzbieta","family":"Jacek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Crow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P.","family":"Wormser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Alaedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2012.10.011_bb0005","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1128\/CMR.18.3.484-509.2005","article-title":"Diagnosis of lyme borreliosis","volume":"18","author":"Aguero-Rosenfeld","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1128\/IAI.67.1.173-181.1999","article-title":"The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 correlates with mild and brief arthritis","volume":"67","author":"Akin","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0015","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.4049\/jimmunol.178.10.6590","article-title":"Immune cross-reactivity in celiac disease: anti-gliadin antibodies bind to neuronal synapsin I","volume":"178","author":"Alaedini","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0020","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0025-6196(11)60731-3","article-title":"Diagnosis and treatment of Lyme disease","volume":"83","author":"Bratton","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0006-8993(99)01328-1","article-title":"Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha","volume":"835","author":"Campbell","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0030","first-page":"590","article-title":"Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease","volume":"44","author":"CDC","year":"1995","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0040","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.bbi.2010.03.002","article-title":"Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms","volume":"6","author":"Chandra","year":"2010","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clim.2011.06.005","article-title":"Epitope mapping of antibodies to VlsE protein of Borrelia burgdorferi in post-Lyme disease syndrome","volume":"141","author":"Chandra","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0045","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/CVI.00002-11","article-title":"Anti-Borrelia burgdorferi antibody profile in post-Lyme disease syndrome","volume":"18","author":"Chandra","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.jneuroim.2012.10.011_bb0050","first-page":"S5","article-title":"Type I interferon in organ-targeted autoimmune and inflammatory diseases","volume":"12","author":"Crow","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-0173(97)00029-5","article-title":"Is interferon-alpha a neuromodulator?","volume":"26","author":"Dafny","year":"1998","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0006-8993(91)91459-E","article-title":"Interferon inhibits synaptic potentiation in rat hippocampus","volume":"564","author":"D'Arcangelo","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0065","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0923-2508(97)85121-2","article-title":"Characterization of a 30-kDa Borrelia burgdorferi substrate-binding protein homologue","volume":"147","author":"Das","year":"1996","journal-title":"Res. Microbiol."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0070","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1212\/01.WNL.0000284604.61160.2d","article-title":"A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy","volume":"70","author":"Fallon","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0075","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMra072023","article-title":"A critical appraisal of \u201cchronic Lyme disease\u201d","volume":"357","author":"Feder","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cytogfr.2012.01.001","article-title":"Interferon-alpha (IFNalpha) neurotoxicity","volume":"23","author":"Fritz-French","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.idc.2007.12.009","article-title":"Nervous system Lyme disease","volume":"22","author":"Halperin","year":"2008","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0090","article-title":"Central administration of murine interferon-alpha induces depressive-like behavioral, brain cytokine and neurochemical alterations in mice: a mini-review and original experiments","author":"Hayley","year":"2012","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0095","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.21890","article-title":"Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies","volume":"54","author":"Hua","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0100","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1128\/iai.61.7.2774-2779.1993","article-title":"Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi","volume":"61","author":"Kalish","year":"1993","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0105","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1002\/art.23728","article-title":"The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus","volume":"58","author":"Kariuki","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM200107123450202","article-title":"Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease","volume":"345","author":"Klempner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eurpsy.2004.09.030","article-title":"Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study","volume":"21","author":"Lieb","year":"2006","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0120","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1128\/jcm.30.2.370-376.1992","article-title":"Serodiagnosis of Lyme borreliosis by western immunoblot: reactivity of various significant antibodies against Borrelia burgdorferi","volume":"30","author":"Ma","year":"1992","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.idc.2007.12.011","article-title":"Chronic Lyme disease: a review","volume":"22","author":"Marques","year":"2008","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0006-8993(00)02877-8","article-title":"Interferon-alpha inhibits long-term potentiation and unmasks a long-term depression in the rat hippocampus","volume":"885","author":"Mendoza-Fernandez","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0135","doi-asserted-by":"crossref","first-page":"8492","DOI":"10.4049\/jimmunol.181.12.8492","article-title":"A critical role for type I IFN in arthritis development following Borrelia burgdorferi infection of mice","volume":"181","author":"Miller","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0140","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus","volume":"8","author":"Niewold","year":"2007","journal-title":"Genes Immun."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0145","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/art.23613","article-title":"Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients","volume":"58","author":"Niewold","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0150","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/IAI.00189-06","article-title":"Serologic proteome analysis of Borrelia burgdorferi membrane-associated proteins","volume":"74","author":"Nowalk","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0155","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/emmm.201000120","article-title":"A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients","volume":"3","author":"Pothlichet","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0160","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.biopsych.2008.08.010","article-title":"Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression","volume":"65","author":"Raison","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0165","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.4049\/jimmunol.171.5.2660","article-title":"Coevolution of markers of innate and adaptive immunity in skin and peripheral blood of patients with erythema migrans","volume":"171","author":"Salazar","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0175","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1097\/QAD.0b013e3282f08c2f","article-title":"Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-alpha in the brain","volume":"21","author":"Sas","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0170","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1523\/JNEUROSCI.5595-08.2009","article-title":"Interferon-alpha causes neuronal dysfunction in encephalitis","volume":"29","author":"Sas","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0180","doi-asserted-by":"crossref","first-page":"e37000","DOI":"10.1371\/journal.pone.0037000","article-title":"Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients","volume":"7","author":"Somers","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0185","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0140-6736(03)14798-8","article-title":"Lyme borreliosis","volume":"362","author":"Stanek","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0190","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.idc.2008.01.001","article-title":"Lyme disease: European perspective","volume":"22","author":"Stanek","year":"2008","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM200107123450207","article-title":"Lyme disease","volume":"345","author":"Steere","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0200","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.ajpath.2011.02.018","article-title":"Borrelia burgdorferi RST1 (OspC type A) genotype is associated with greater inflammation and more severe Lyme disease","volume":"178","author":"Strle","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0205","series-title":"Wechsler Memory Scale","author":"Wechsler","year":"1997"},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0215","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1086\/314922","article-title":"Association of specific subtypes of Borrelia burgdorferi with hematogenous dissemination in early Lyme disease","volume":"180","author":"Wormser","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jneuroim.2012.10.011_bb0210","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/508667","article-title":"The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America","volume":"43","author":"Wormser","year":"2006","journal-title":"Clin. Infect. Dis."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572812003141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572812003141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:19:51Z","timestamp":1759047591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572812003141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":43,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0165572812003141"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2012.10.011","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased IFN\u03b1 activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2012.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}